



Press Release

HCL and IIT Delhi come together to create next generation of drugs

Noida, May 3rd, 2005: HCL technologies Ltd ("HCL"), a leading Global IT and Technology enterprise has signed a MoU with the 'Supercomputing Facility for Bioinformatics and Computational Biology' (SCFBio) at IIT Delhi to work collaboratively on high-end projects in the area of drug discovery and development including genomics and proteomics projects. HCL plans to team up with premier Bioinformatics research institutions across the world to build fundamental capabilities and grow talent pool in India in this domain.

The Life Sciences practice at HCL provides tested solutions in areas like Pharmacogenomics, RFID-based drug counterfeit solutions, medical devices and diagnostics, contract manufacturing, and hospital information systems. HCL will use its CMMI processes and robust software design methodology to leverage the domain expertise of the team at IIT Delhi.

SCFBio is dedicated to developing novel scientific methods and new software for genome analysis, protein structure prediction and active site-directed drug design. This partnership will also provide the researchers access to HCL's software development expertise.

"It is pivotal to do science that is eventually realized into technology for the benefit of society. We at SCFBio are excited to enter into collaboration with HCL, bridging the gap between industry know-how and academia R&D. HCL with its strong IT skills and market exposure brings an opportunity for us to focus our R&D more concretely in meeting industry's requirements and standards" said Pankaj Sharma, Project Scientist & System Administrator, SCFBio IIT Delhi.

HCL has setup India's first network dedicated to Bioinformatics research – Biogrid. Currently twelve research institutes are using this network to collaborate on research projects. This network would help the scientists and students across the country to access Supercomputing resources from any of these centers. The centers that have been currently linked to Biogrid are IISc, University of Pune, IGIB, NII, NBRC, IIT Delhi, University of Delhi South Campus, Madurai Kamraj University, University of Pune, IMTech Chandigarh, JNU, CDFD and DBT. These centers are pursuing R&D in bioinformatics besides disseminating biotechnology information to the researchers around the world. Biogrid will be also useful in sharing teaching materials, to deliver lectures through video conferencing-virtual classrooms besides synergizing research in biotechnology and bioinformatics.

Commenting on the alliance, Mr. Pradep Nair, Head of HCL's Life Sciences practice said, "We are extremely proud of the kind of work that we are doing in the practice. We are developing next generation medical devices, drug development tools utilizing



IP protected molecular designing algorithms, Clinical Data and Trial Management solutions using widest electronic data capture options for Pharmaceutical and Clinical Research Organizations. By associating with Research institutes and private companies in the area of pharma R&D, we are continuously strengthening our domain capabilities for our global markets."

Mr. K.K. Roy, from Foundation of Innovation and Technology transfer, the industry interface unit in IIT Delhi, added that, "a platform has been created for free interaction of the technologies in HCL with expertise in SCFBio for collaborative research, project execution and commercialization of research results."

About HCL's Life Sciences Practice

The Life Sciences practice at HCL delivers IT centric solutions across the Pharmaceutical, medical device, diagnostics and hospital industries. The DNA of the practice lies in extension of this knowledge to provide focused IT services and solutions to the customers. HCL's investments have strong focus on regulatory compliance prescribed by FDA's CFR, CEC, ISO, HIPAA and meeting technology paradigms surrounding HL7, DICOM, amongst others. HCL continues to invest in providing tested solutions in thought leadership arenas like Pharmacogenomics, RFID-based drug counterfeit solutions, medical devices and diagnostics, contract manufacturing, and hospital information systems.

The Life Sciences team comprises of 500 people including regulatory experts, bio technologists, pharmaceutical industry experts etc. HCL is already working with 6 of the top 10 leading global pharmaceutical companies including Novartis, Aventis etc.

About HCL Enterprise

HCL Enterprise is a leading Global Technology and IT enterprise with annual revenues in excess of \$2.0 billion. IT Products and Services contribute to revenues of over \$1.1 billion. The HCL Enterprise comprises of two companies listed in India, HCL Technologies & HCL Infosystems. The 29 year old enterprise, founded in 1976, is one of India's original IT garage start ups. Its range of offerings span Product Engineering, Technology and Application Services, BPO, Infrastructure Services, IT Hardware, Systems Integration, and distribution of technology and telecom products. The HCL team comprises of 25,000 professionals of diverse nationalities, who operate from 15 countries including 300 points of presence in India. HCL has global partnerships with several leading Fortune 1000 firms, including leading IT and Technology firms. For more information please visit www.hcl.in

About HCL Technologies

HCL Technologies is one of India's leading global IT Services Company, providing software- led IT solutions, BPO and Remote Infrastructure Management services. Making a foray into the services domain in 1997-98, HCL Technologies focuses on technology and R&D outsourcing, working with clients in areas at the core of their business. The company leverages an extensive offshore infrastructure and its global network of 26 offices in 15 countries to deliver solutions across select verticals including Banking, Insurance, Retail & Consumer, Aerospace, Automotive, Semiconductors, Telecom and Life Sciences. For the twelve month period ended 31st March 2005, HCL Technologies along with its subsidiaries had revenues of \$ 711 million and employed 22,034 professionals. For more information, please visit www.hcltech.com

Forward Looking Statements

Certain statements in this release are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international



operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies/ entities in which we have made strategic investments, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. The company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the company.

For further information please contact:

Manisha Singh HCL Technologies A 10/11, Sector 3, NOIDA -201301, India Tel: 95-120-2520917 e-mail: manishasingh@corp.hcltech.com	Alka Sharma Genesis Tel: +91 9811546200 Fax : (91-0124) 5044744 e-mail: asharma@genesispr.com
---	--